Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
Researchers Uncover Decline in Cardiovascular Health Among Middle-Aged Adults and Persistent Income-Based Inequities
11/28/2023

Jacqueline Mitchell
Beth Israel Deaconess Medical Center News

Jacqueline MitchellBeth Israel Deacon...
New research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) helps explain the recent reversal in cardiovascular mortality among this population and underscores the need to address the social determinants of health that...
New research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) helps explain the recent reversal in cardiovascular mortality among this population and underscores the need to address the social determinants of health that...
New research led by...
11/28/2023
Cath Lab Digest
News
Left Atrial Appendage Closure More Effective than Blood Thinners to Prevent Deadly Stroke Complications in Afib Patients
11/27/2023

Mount Sinai News

Mount Sinai News
This is the largest study of its kind comparing outcomes of strokes from a blood clot from the heart in atrial fibrillation patients treated with LAAC versus blood thinners. 
This is the largest study of its kind comparing outcomes of strokes from a blood clot from the heart in atrial fibrillation patients treated with LAAC versus blood thinners. 
This is the largest study of its...
11/27/2023
Cath Lab Digest
News
ARIES-HM3: Study Shows Aspirin May Not Be Necessary With LVAD
11/21/2023

Ochsner Health News

Ochsner Health News
A groundbreaking study recently published in JAMA indicates that aspirin may not be necessary as part of an antithrombotic regimen for patients with a fully magnetically levitated left ventricular assist device (LVAD).
A groundbreaking study recently published in JAMA indicates that aspirin may not be necessary as part of an antithrombotic regimen for patients with a fully magnetically levitated left ventricular assist device (LVAD).
A groundbreaking study recently...
11/21/2023
Cath Lab Digest

Advertisement

News
PROFID EHRA: Trial to Prevent Sudden Death After Heart Attack Enrolls First Patient
11/21/2023

European Society of Cardiology News

European Society of Cardiology News ...
The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.
The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.
The first clinical trial to...
11/21/2023
Cath Lab Digest
FDA Approval
Medtronic Launching New Frontier in Treating High Blood Pressure With FDA Approval of Symplicity Spyral Renal Denervation System
11/20/2023

Medtronic News

Medtronic News
Manufacturing of the device for U.S. distribution is already underway, and Medtronic hopes to make it widely available soon to physicians and healthcare systems.
Manufacturing of the device for U.S. distribution is already underway, and Medtronic hopes to make it widely available soon to physicians and healthcare systems.
Manufacturing of the device for...
11/20/2023
Cath Lab Digest
News
Cordis Announces Enrollment Completion of the RADIANCY Clinical Study in Europe
11/17/2023

Cordis News

Cordis News
The S.M.A.R.T. RADIANZ™ Vascular Stent System, specifically engineered for radial access, was approved for use in the United States by the FDA in February 2022, and in Japan by PMDA in March 2022.
The S.M.A.R.T. RADIANZ™ Vascular Stent System, specifically engineered for radial access, was approved for use in the United States by the FDA in February 2022, and in Japan by PMDA in March 2022.
The S.M.A.R.T. RADIANZ™ Vascular...
11/17/2023
Cath Lab Digest

Advertisement

News
Teleflex Announces First Patient Enrollment in ACCESS-MANTA Registry
11/17/2023

Teleflex News

Teleflex News
Available in 14 and 18 Fr. sizes, the MANTA™ Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20 Fr. devices or sheaths (12-25 Fr. O.D.) in endovascular procedures.
Available in 14 and 18 Fr. sizes, the MANTA™ Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20 Fr. devices or sheaths (12-25 Fr. O.D.) in endovascular procedures.
Available in 14 and 18 Fr....
11/17/2023
Cath Lab Digest
News
Xenter Unveils Investigational Dual Sensor Wireless GuideWire for Minimally Invasive TAVR Procedures at TCT 2023
11/14/2023

Xenter News

Xenter News
The guidewire’s functionality is designed to allow for comprehensive data collection and analysis and facilitates data necessary for novel Artificial Intelligence (AI) decision-making tools.
The guidewire’s functionality is designed to allow for comprehensive data collection and analysis and facilitates data necessary for novel Artificial Intelligence (AI) decision-making tools.
The guidewire’s functionality is...
11/14/2023
Cath Lab Digest
News
SELECT Trial: Major CVD Event Risk Cut by 20% in Overweight or Obese Adults Without Diabetes
11/13/2023

American Heart Association News

American Heart Association News ...
Study participants were randomly assigned to either 2.4 mg of semaglutide (FDA-approved dose for weight management) or a placebo 1x/week, which is higher than the FDA-approved semaglutide dose limit for Type 2 diabetes of 2.0 mg/week.
Study participants were randomly assigned to either 2.4 mg of semaglutide (FDA-approved dose for weight management) or a placebo 1x/week, which is higher than the FDA-approved semaglutide dose limit for Type 2 diabetes of 2.0 mg/week.
Study participants were randomly...
11/13/2023
Cath Lab Digest

Advertisement

News
ORBITA-2 Confirms Benefit of Percutaneous Coronary Intervention in Patients with Chronic Coronary Artery Disease
11/13/2023

The Society for Cardiovascular Angiography & Interventions (SCAI) News

The Society for Cardiovascular Angiog...
ORBITA-2 is the first sham-controlled trial to confirm the benefit of percutaneous coronary intervention (PCI) for patients with stable ischemic heart disease.
ORBITA-2 is the first sham-controlled trial to confirm the benefit of percutaneous coronary intervention (PCI) for patients with stable ischemic heart disease.
ORBITA-2 is the first...
11/13/2023
Cath Lab Digest

Advertisement

Advertisement

Subscriber

Cath Lab Digest Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use